Table 1.
Biologics for the treatment of moderate to severe psoriasis in adults approved or filed for approval by the United States Food and Drug Administration as of June 2019
| Biologic drug | Therapeutic target | Approval date | Other approved indications/notes |
|---|---|---|---|
| Etanercept | TNF | April 2004 |
Moderate to severe rheumatoid arthritis (November 1998) Moderate to severe polyarticular juvenile idiopathic arthritis (≥2 years) (May 1999) Psoriatic arthritis (January 2002) Ankylosing spondylitis (July 2003) Paediatric (4–17 years) chronic moderate to severe psoriasis (November 2016) |
| Infliximab | TNF | September 2006 |
Crohn's disease (August 1998) Rheumatoid arthritis (November 1999) Ankylosing spondylitis (December 2004) Psoriatic arthritis (May 2005) Ulcerative colitis (September 2005) Paediatric (≥6 years) Crohn's disease (May 2006) Paediatric (≥6 years) ulcerative colitis (September 2011) |
| Adalimumab | TNF | January 2008 |
Rheumatoid arthritis (December 2002) Psoriatic arthritis (October 2005) Ankylosing spondylitis (July 2006) Crohn's disease (February 2007) Polyarticular juvenile idiopathic arthritis (≥2 years) (February 2008) Ulcerative colitis (September 2012) Paediatric (≥6 years) Crohn's disease (September 2014) Moderate to severe hidradenitis suppurativa (≥12 years) (September 2015) Uveitis (≥2 years) (June 2016) |
| Ustekinumab | IL‐12/IL‐23p40 | September 2009 |
Active psoriatic arthritis (September 2013) Moderately to severely active Crohn's disease (September 2016) Adolescent (≥12 years) moderate to severe psoriasis (October 2017) |
| Secukinumab | IL‐17A | January 2015 |
Active psoriatic arthritis (January 2016) Active ankylosing spondylitis (January 2016) |
| Ixekizumab | IL‐17A | March 2016 | Active psoriatic arthritis (December 2017) |
| Brodalumab † | IL‐17A receptor | February 2017 | — |
| Guselkumab | IL‐23p19 | July 2017 | — |
| Tildrakizumab | IL‐23p19 | March 2018 | — |
| Certolizumab pegol | TNF | May 2018 |
Moderate to severe Crohn's disease (April 2008) Moderately to severely active rheumatoid arthritis (May 2009) Active psoriatic arthritis (September 2013) Active ankylosing spondylitis (October 2013) |
| Risankizumab | IL‐23p19 | Filed for approval April 2019 | — |
†Availability restricted through a Risk Evaluation and Mitigation Strategy (REMS) programme in the United States.
IL, interleukin; TNF, tumour necrosis factor.